Startseite
Kongressberichte 2020
61st ASH Annual Meeting and Exposition
Immunotherapies
Immunotherapies I
704. Immunotherapies I
199
LaQuisa C. Hill, et al.
Conclusion cited from the abstract:
These results demonstrate that CD5 CAR T cells are safe and can induce clinical responses in heavily treated patients with r/r CD5+ T-ALL and T-NHL without inducing complete T-cell aplasia. Importantly, elimination of malignant T cells by CD5 CAR T cells may allow previously ineligible patients to proceed to HSCT.
Double-click:
200
Chiara F Magnani et al.
Conclusion cited from the abstract:
Our ongoing phase I/II trial demonstrates that SB-engineered CARCIK-CD19 cells are able to expand and persist in pediatric and adult B-ALL patients relapsed after HSCT, with important implications for a non-viral technology. These encouraging results prompted us to expand our study.
201
Evandro D. Bezerra, et al.
Conclusion cited from the abstract: Our findings suggest outcomes after second infusions of CD19 CAR-T cells might be improved with high-intensity CyFlu lymphodepletion prior to CART1 and by increasing the CAR-T cell dose at the time of CART2.
Double-click:
202
David J. Reiss, et al.
Conclusion cited from the abstract: Overall, these data suggest that increased infiltration of tumor-specific CAR T cells upon initial treatment with liso-cel helped establish an active immune response, and that recruitment of additional functional endogenous (particularly CD4+) T cells correlated with durable response. Higher numbers of activated/functional T cells and lower numbers of macrophages prior to treatment also correlated with durable response to liso-cel. Thus, tumors in responders may already have had a baseline TME in which T cells could infiltrate and respond to antigen. This may have promoted the success of CAR T cell entry into tumors and the subsequent recruitment and activation of endogenous lymphocytes that support their function.
03
Sattva S Neelapu, et al.
Conclusion cited from the abstract:
In this cohort of patients relapsing after axi-cel, loss of CD19 expression was common by IHC as compared to pretreatment, likely due to alternative splicing and selection of variants devoid of target epitope. Additionally, the data showed that expression of alternate B cell lineage antigens was largely preserved. In particular, CD20 cell surface expression was strong in most tumors despite prior rituximab-based treatments. Altogether, these data point to strategies to improve efficacy of anti-CD19 CAR T cell products through co-targeting or sequential targeting of alternate B cell antigens.
Double-click:
204
Andrew J. Cowan, et al.
Conclusion cited from the abstract: Although BCMA CAR T cell therapy has demonstrated potent anti-tumor efficacy in multiple myeloma, a significant proportion of patients relapse. The mechanism of myeloma recrudescence requires further study, however BCMA antigen loss has been observed after CAR T cell therapy and is a putative pathway for tumor escape. In this study we demonstrate that gamma secretase inhibition with JSMD194 routinely increases BCMA surface density on myeloma cells in treated patients and reduces soluble BCMA. The combination of a gamma secretase inhibitor with BCMA CAR T cells leads to rapid responses including in patients that have failed prior BCMA targeted therapy. These responses are achieved with low CAR T cell doses. Longer follow up is required to determine if the durability of response is improved.
66
Donald L. Patrick, Annette Powers, Monika Parisi, Yeonhee Kim, et al.
In TRANSCEND NHL 001, pts in the DLBCL cohort experienced an improvement in HRQoL and health utility through Month 12, though some reported a detriment at Month 1. Reduced fatigue and pain symptom burden through Month 12 after liso-cel infusion was also reported. Overall, in spite of the limitations inherent in the study, a notable proportion of pts demonstrated clinically meaningful improvements at Months 6 and 12.
